Plain-English translation of NCT07777484 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson's Disease research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a small pilot study testing a vaccine called designed for people with Parkinson's disease who have already received a previous immunotherapy treatment targeting alpha-synuclein. The study will check whether this follow-up medication is safe, well-tolerated, and produces the expected immune response in your body. You would receive one or possibly two injections over a few weeks, with close monitoring by the research team.
Researchers are exploring whether a follow-up vaccination can safely build on the benefits of previous Parkinson's immunotherapy treatments. This early-stage study will help determine if this treatment approach is worth pursuing in larger research efforts.
You likely qualify if…
You likely don't qualify if…
You would receive one injection of the medication at the start of the study (week 0). Depending on how well you tolerate it and how your immune system responds, you may be offered a second injection 4 to 6 weeks later. The research team will monitor you closely for safety and take blood samples to check your immune response. The entire study involves a small number of participants (about 6 people total), making this a careful, early-stage test of the treatment.
AI-generated summary from trial data · Aug 20, 2026 · Not medical advice
Austria